Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
2021 · Breast Cancer Research · 150 citations
https://doi.org/10.1186/s13058-021-01492-x
G
Gabriel Rinnerthaler
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
184
Papers
2.7K
Citations
26
h-index
49
i10-index
Gabriel Rinnerthaler is an academic researcher from Medical University of Graz. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research. The author has an h-index of 26, co-authored 157 publications.
ORCID: 0000-0001-7438-1465Papers by this author
worksHypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
2014 · PubMed · 44 citations
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
2018 · Nature Communications · 24 citations
https://doi.org/10.1038/s41467-018-03631-z
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group
2022 · ESMO Open · 19 citations
https://doi.org/10.1016/j.esmoop.2022.100747
Bone-Targeted Therapy in Metastatic Breast Cancer - All Well-Established Knowledge?
2014 · Breast Care · 17 citations
https://doi.org/10.1159/000368710
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
2015 · PubMed · 13 citations
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat